cohbar
participate
roth
capital
therapeutics
development
event
menlo
park
globe
newswire
cohbar
nasdaq
cwbr
clinical
stage
biotechnology
company
developing
mitochondria
based
therapeutics
treat
chronic
diseases
extend
healthy
lifespan
announced
today
chief
executive
officer
steven
engle
chief
scientific
officer
kenneth
cundy
participate
panel
titled
direct
antivirals
agents
virus
roth
capital
therapeutics
development
event
held
virtually
october
pt
live
webcast
presentation
available
attendees
register
https
webinar
register
panelists
discuss
key
therapies
novel
emerging
approaches
development
potential
treatments
engle
cundy
joined
tarek
hassanein
professor
medicine
ucsd
hepatologist
biotech
company
leaders
aridis
pharmaceuticals
hepion
pharmaceuticals
durect
corporation
beyond
air
panel
moderated
roth
analysts
scott
henry
cfa
zegbeh
jallah
elemer
piros
cohbar
plans
present
information
analogs
shown
potential
therapeutics
associated
acute
respiratory
distress
syndrome
ards
based
reduction
fluid
accumulation
cytokine
secretion
neutrophil
infiltration
preclinical
model
ards
analogs
shown
vitro
activate
apelin
receptor
initiates
cell
signaling
pathway
shown
published
preclinical
studies
broad
protective
effects
apelin
signaling
may
potentially
reduce
severity
acute
lung
injury
reducing
lung
fluid
accumulation
hypoxemia
cytokine
secretion
primary
consequences
severe
infection
leading
ards
downstream
injury
kidney
heart
organs
cohbar
cohbar
nasdaq
cwbr
clinical
stage
biotechnology
company
focused
research
development
mitochondria
based
therapeutics
emerging
class
drugs
treatment
chronic
diseases
mitochondria
based
therapeutics
originate
discovery
cohbar
founders
novel
group
naturally
occurring
peptide
sequences
within
mitochondrial
genome
shown
potential
regulate
key
processes
multiple
systems
organs
body
date
company
discovered
mitochondrial
derived
peptides
generated
analogs
cohbar
efforts
focus
development
peptides
therapeutics
offer
potential
address
broad
range
diseases
underlying
impact
mitochondrial
dysfunction
company
lead
compound
phase
stage
phase
clinical
trial
nash
obesity
addition
cohbar
four
preclinical
programs
analogs
fibrotic
diseases
analogs
associated
ards
analogs
cancer
orphan
diseases
analogs
cancer
immunotherapy
additional
company
information
please
visit
statements
news
release
contains
statements
historical
facts
within
meaning
private
securities
litigation
reform
act
statements
based
current
beliefs
expectations
assumptions
regarding
future
business
future
plans
strategies
projections
anticipated
events
future
conditions
cases
identify
statements
words
believe
may
estimate
continue
anticipate
intend
could
would
project
plan
expect
goal
seek
future
likely
negative
plural
words
similar
expressions
examples
statements
include
limited
statements
regarding
anticipated
outcomes
research
clinical
trials
mitochondria
based
therapeutic
mbt
candidates
expectations
regarding
growth
mbts
significant
future
class
drug
products
statements
regarding
anticipated
therapeutic
properties
potential
mitochondrial
peptide
analogs
mbts
potential
therapies
including
limited
potential
treatment
associated
ards
cautioned
statements
guarantees
future
performance
actual
results
developments
may
differ
materially
set
forth
statements
factors
could
cause
actual
results
differ
materially
statements
include
ability
successfully
advance
drug
discovery
development
programs
including
delay
termination
ongoing
clinical
trials
possible
inability
mitigate
prevalence
persistence
injection
site
reactions
receipt
unfavorable
feedback
regulators
regarding
safety
tolerability
possibility
developments
affecting
viability
clinical
candidate
commercial
potential
results
different
earlier
data
results
including
less
favorable
may
support
clinical
development
ability
raise
additional
capital
necessary
continue
operations
ability
recruit
retain
key
management
scientific
personnel
risk
intellectual
property
may
adequately
protected
ability
establish
maintain
partnerships
corporate
industry
partners
risks
related
impact
business
pandemic
similar
public
health
crises
additional
assumptions
risks
uncertainties
described
detail
registration
statements
reports
filings
securities
exchange
commission
applicable
canadian
securities
regulators
available
website
cautioned
statements
guarantees
future
performance
actual
results
may
differ
materially
set
forth
statements
statements
information
contained
news
release
made
date
hereof
cohbar
undertake
obligation
update
publicly
revise
statements
information
whether
result
new
information
future
events
otherwise
unless
required
applicable
securities
laws
nothing
herein
shall
constitute
offer
sell
solicitation
offer
buy
securities
contacts
jordyn
tarazi
director
investor
relations
cohbar
joyce
allaire
lifesci
advisors
llc
jallaire
